



## 2022-2023 ECCO Annual Disclosure of Potential Conflict of Interest

**Name:** Jairath, Vipul

In its aim to foster transparency and based on the ICJME Disclosure Form for Potential Conflict of Interest, ECCO has collected the according information of ECCO Officers and invited congress faculty at ECCO'23 via its online submission system.

The CoI Disclosure information is updated every autumn in line with the respective Congress business year. The purpose is to have a comprehensive declaration of interests for ECCO activities.

In case different disclosure answers have been submitted for different ECCO'23 presentations, the 2022-2023 ECCO Annual Disclosure of Potential Conflict of Interest on the association website shows the merged version of the answers to the following questions:

- Disclosure statement:
  - I have no potential conflict of interest to disclose
  - I have potential conflict of interest to disclose
- Potential Conflict of Interest can involve: grants, honoraria, shares, paid positions on advisory boards, etc.:
  - Grant
  - Personal Fees
  - Non-financial support
  - Other

### **Disclosures statement based on answers received:**

**Grant:** |Celgene/BMS, Pfizer, Abbvie, Boehringer Ingelheim, Eli Lilly, Janssen, Takeda, Gilead Sciences, Tigenix| **Personal Fees:** |AbbVie, Alimentiv Inc. (formerly Robarts Clinical Trials Inc.) , Amgen, Anokion, Applied Strategic, Arena Pharmaceuticals, Asahi Kasei Pharma, Asieris, Astra Zeneca, BioJamp. Celgene/BMS, Celltrion, Eli Lilly, Ferring, F. Hoffman-La Roche Ltd., Flagship Pioneering, Fresenius Kabi, Fusion MD Network, Galapagos, Genentech, Gilead, GlaxoSmithKline, Janssen , Knightslab, Organon (Merck), Landos BioPharma, McKesson, Metacrine, Mylan, Pandion, Pendopharm, Pfizer, Prometheus, Protagonist Therapeutics, Reistone Biopharma, Roche, Sandoz, Second Genome, Sorriso, Takeda, Teva, Topivert, Ventyx Biosciences, Viatrix, Vividion Therapeutics